Clinical Trials Logo

Uterine Cervical Dysplasia clinical trials

View clinical trials related to Uterine Cervical Dysplasia.

Filter by:

NCT ID: NCT04751799 Completed - Pain Clinical Trials

Virtual Reality: Influence on Satisfaction, Pain, and Anxiety in Patients Undergoing Colposcopy

Start date: May 25, 2021
Phase: N/A
Study type: Interventional

Cervical cancer is one of the most common cancers in women and one of the leading causes of death in women worldwide. Pre-cancerous lesions (dysplasias) are detected by the screening smear test at the gynecologist's office and can thus contribute to a 100% chance of cure if they are clarified by a colposcopic examination as part of the dysplasia consultation. To detect cervical dysplasia during colposcopic examination, the effect of diluted acetic acid on the epithelium of the cervix uteri is utilized. Metaplastic epithelium and low-grade dysplasia are visually noticeable by a slight white staining. Biopsies are then taken from these areas for further diagnosis. The colposcopy itself and especially the colposcopic targeted biopsy of the cervix are painful. Virtual reality (VR) is a new method for 360° three-dimensional viewing of image content. A number of studies have shown that the use of VR can have a positive impact on the course of medical interventions. Randomized studies on the effectiveness of VR in a collective of women with colposcopically targeted biopsy of the cervix are not available according to a recent literature search (PubMed search of 12/30/2020; search terms: cervical biopsy, colposcopy, pain relief, pain control, virtual reality). In studies of our research group on colposcopy, we found increased pain scores especially in younger patients, but also in obese patients and smokers. A controlled study on the effectiveness of VR in colposcopically targeted biopsy is therefore useful. In our study, we now want to answer the question under prospective conditions whether the use of VR before the start or before the start and during colposcopy compared to no intervention leads to a significant increase in patient satisfaction and/or a reduction in pain in the context of clarification colposcopy and colposcopically targeted biopsy.

NCT ID: NCT04742543 Recruiting - Dysplasia, Cervix Clinical Trials

Virtual Reality During Conization of Cervix Uterus Under Local Anesthesia

Start date: May 19, 2022
Phase: N/A
Study type: Interventional

To evaluate the effectiveness of virtual reality glasses as a distraction technique in the management of acute pain and anxiety during conization of cervix uterus under local anesthesia

NCT ID: NCT04712851 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Start date: June 30, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT04679675 Completed - Cervical Cancer Clinical Trials

Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial

STEP
Start date: November 20, 2020
Phase: N/A
Study type: Interventional

The Self-Testing options in the Era of Primary HPV screening for cervical cancer (STEP) trial will evaluate effectiveness of home-based HPV kits for improving cervical cancer screening uptake and its cost-effectiveness. The investigators will compare cervical cancer screening uptake within six months among women randomized to different outreach approaches based on prior screening behavior: A) Adherent and coming due: direct mail HPV kit vs. opt-in HPV kit vs. education; B) Overdue: direct mail HPV kit vs. education; C) Unknown: opt-in HPV kit vs. education.

NCT ID: NCT04537156 Active, not recruiting - Cervical Cancer Clinical Trials

Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Start date: September 5, 2020
Phase: Phase 3
Study type: Interventional

This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women aged 18-45 years old.

NCT ID: NCT04472455 Completed - Cervical Cancer Clinical Trials

Mobile High-Resolution Microendoscopy (mHRME) for the Detection of Cervical Dysplasia in El Salvador

Start date: September 2015
Phase:
Study type: Observational

Evaluate the performance of the mHRME in a study of 3,000 women in San Salvador to assess whether mHRME imaging improves specificity of screening by VIA or HPV DNA without reducing sensitivity for cervical precancer and cancer.

NCT ID: NCT04415840 Completed - Clinical trials for Uterine Cervical Dysplasia

Lugol's Solution in Addition to Acetic Acid During Colposcopy

Start date: May 31, 2020
Phase:
Study type: Observational

To assess the benefits of using Lugol's solution in addition to acetic acid during colposcopy in women with cervical dysplasia.

NCT ID: NCT04326049 Completed - Clinical trials for Uterine Cervical Dysplasia

LLETZ With Videocolposcopy Versus LLETZ With Binocular Colposcopy

Start date: March 25, 2020
Phase: N/A
Study type: Interventional

To assess the benefits of performing large Loop excision of the transformation Zone (LLETZ) using videocolposcopy compared to binocular colposcopy.

NCT ID: NCT04298957 Completed - Cervical Dysplasia Clinical Trials

See and Treat in an Outpatient Setting in Women Above 45 Years With Cervical Dysplasia

Start date: March 13, 2019
Phase: N/A
Study type: Interventional

The study will investigate if implementation of "see and treat" in the outpatient clinic can optimize the diagnosis, clinical follow-up and treatment of older women with positive cervical screening test.

NCT ID: NCT04278326 Recruiting - Cervical Cancer Clinical Trials

Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments

ORGANOIDES
Start date: March 6, 2020
Phase: N/A
Study type: Interventional

Human papilloma virus (HPV) is responsible of the most common sexually transmitted infection. It can cause severe cancer lesions, of the cervix, vulva, vagina, penis and oropharynx. The International Agency for Cancer Research of World Health Organization (WHO) classified a dozen of HPV related high-risk cancer types, and recognized cervical cancer as the most common HPV-related disease. HPV 16 and 18 are responsible for 70% of cervical cancers. Due to the few symptoms of cervical cancer, women are often diagnosed with advanced state. Current treatments imply cervical conisation or hysterectomy, with or without lymphadenectomy and or radiotherapy, or chemotherapy. However, few pharmacological options are available against oncogenic papilloma viruses and thus against recurrences The aim of this project is to develop relevant organoids models from patient biopsies that will be used to identify biomarkers and evaluate in a closest preclinical setting novel nucleic acids based therapeutic strategy for HPV-cervical-vaginal dysplasia and cancers.